Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company whose common stock trades on the Nasdaq under the ticker NEUP. The company is the successor to Bionomics Limited, an Australian drug developer that redomiciled to the United States and adopted the Neuphoria name in 2024.

Neuphoria focuses on treatments for neuropsychiatric disorders with significant unmet need. Its lead candidate, BNC210, is an oral negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor that is being developed for the acute treatment of social anxiety disorder and for post-traumatic stress disorder. The drug is designed to relieve anxiety without the sedation and dependence issues associated with some existing medicines.

The company also holds earlier-stage programs targeting ion channels in the brain, including compounds partnered with other pharmaceutical companies for cognitive and central nervous system disorders.